Advertisement


Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

2023 ASCO Annual Meeting

Advertisement

Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes (radiographic progression–free-survival and overall survival) were observed in men receiving the standard of care plus abiraterone acetate plus prednisone with radiotherapy (Abstract LBA5000).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Alberto Bossi, MD: PEACE-1 is a randomized Phase III trial with four arms that has been designed some 11 years ago in order to study a very precise population of patients, which is patients presenting de novo of diagnosis with metastatic prostate cancer. There has been a huge landscape movement in the last years concerning this subgroup of patients and PEACE-1 has specifically been designed to answer two questions. First of all, the benefit of abiraterone on top of standard of care, and second, to detect if any benefit of local radiotherapy, prostate radiotherapy would be important for those patients, so two questions, four arms. Standard of care has been updated during the inclusion period of the study because we had some new evidence coming from the literature, and so the use of chemotherapy, docetaxel, has been at first introduced and compulsory at the end of the trial, four arms, so that have been compared and two main endpoints, radiographic progression-free survival and overall survival. Then a list of secondary endpoints, which we also discuss. What we discovered, in terms of overall survival, no difference between the use of local radiotherapy in those patients, both in the low volume population so patients presenting with low volume metastatic disease as in the high volume population, patients presenting with high burden of metastatic disease, no impact of radiotherapy. But using radiotherapy translates in a better radiographic progression-free survival, which was the second co-primary endpoint. We then had a list of secondary endpoints and we made studies on three of them. First, castration resistant state, and we discovered that giving radiotherapy in the prostate on those patients delays the onset of the castration resistant state, and this in a significant way. And second, that also in terms of secondary events locally in the prostate, radiotherapy may delay the need of a secondary treatment for those patients. Altogether, I think that in terms of quality of life for our patients these are very important outcomes. What's next? Well, first we have to dig into those data with much more details. There are still some open questions there. You are probably aware of the result of the STAMPEDE trial, the English trial which has exactly done the same as our trial and that has shown an improvement in overall survival, why our data do not show the same, so this is something we will try to dig later on. And secondary, there are a list of other endpoints which we also will try to study more details. The secondary endpoints are also important, especially in terms of quality of life for our patients. What is reassuring, and this is the end, what is reassuring is that no added toxicity was due to radiotherapy in the prostate and I think that this is very good and reassuring information for our patients and their family.

Related Videos

Bladder Cancer

Christian Pfister, MD, PhD, on Bladder Cancer: New Overall Survival Data on Perioperative Chemotherapy

Christian Pfister, MD, PhD, of Rouen University Hospital, discusses phase III results from the VESPER trial, which showed that dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin provided a better overall survival rate at 5 years and improved disease-specific survival compared with gemcitabine as perioperative chemotherapy in patients with muscle-invasive bladder cancer (Abstract LBA4507). 

Colorectal Cancer

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Sebastian Stintzing, MD, of the Charité Universitätsmedizin Berlin, discusses results from the phase III FIRE-4 study, which showed that liquid biopsy is clinically relevant in verifying mutational status in patients with metastatic colorectal cancer and is efficacious in first-line treatment of FOLFIRI and cetuximab for patients with RAS wild-type disease (Abstract 3507).

Kidney Cancer

Rana R. McKay, MD, and Toni K. Choueiri, MD, on RCC: New Findings on Efficacy and Safety of Atezolizumab Plus Cabozantinib

Rana R. McKay, MD, of the University of California, San Diego, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discuss results from the phase III CONTACT-03 study, showing that, for patients with metastatic renal cell carcinoma (RCC), adding the PD-L1 inhibitor atezolizumab to cabozantinib did not improve clinical outcomes compared with treatment with cabozantinib alone. In addition, higher toxicities were observed in the combination arm (Abstract LBA4500).

Lymphoma

Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses waveLINE-007, a two-part study now recruiting in more than 20 locations, to determine the safety and recommended phase II dose of the antibody-drug conjugate zilovertamab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). Efficacy of this regimen will be investigated in the second half of the study (Abstract TPS7589).

Bladder Cancer
Immunotherapy

Shilpa Gupta, MD, on Urothelial Carcinoma: Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab

Shilpa Gupta, MD, of Cleveland Clinic, discusses the results from the EV-103 study and the unmet need for effective first-line therapies in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. After nearly 4 years of follow-up, the trial findings showed that enfortumab vedotin-ejfv plus pembrolizumab continues to demonstrate promising survival trends with rapid and durable responses in this population (Abstract 4505).

Advertisement

Advertisement




Advertisement